• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·UPC
Share

Universe Pharmaceuticals Inc. Stocks

$ 3.39Last Updated 24.07.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 2.14M

$ 3.39
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is undervalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.07.2026 18:30

A 10-fold growth, Korea’s golden age, and a lesson from China: Highlights from an interview with the head of Nvidia

27.07.2026 18:02

A Magnet for Startups: Why Are Fintech Startups and Neobanks Flocking to Colombia?

27.07.2026 17:40

Leather bags are no longer driving the luxury market. But a new driver has emerged.

27.07.2026 17:16

Shares of European and U.S. oil giants have plummeted along with oil prices. Is it time to sell them?

27.07.2026 16:55

Shares of the largest supplier of electric vehicle batteries soared after the company announced a buyback

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026